Abstract Plasmid DNA vaccination is an attractive way to elicit T cell responses against infectious agents and tumor cells. DNA constructs can be designed to contain multiple T cell epitopes to generate a diverse immune response to incorporate numerous antigens and to reduce limitations due to MHC restriction into a single entity. We have prepared cDNA plasmid constructs containing several mouse T cell epitopes connected by either furin-sensitive or furin-resistant linkers and studied the eVects of a cationic cell-penetrating sequence from HIV-tat. SigniWcant CD8 T cell responses were obtained with multi-epitope DNA vaccines followed by in vivo electroporation regardless of the type of linker used and whether the construct had the HIV-tat sequence. The magnitude of immune responses was very similar to all CD8 T cell epitopes contained within each vaccine construct, indicating the absence of immunodominance. Incorporating a T helper epitope into the constructs increased the T cell responses. Prophylactic and therapeutic antitumor responses against B16 melanoma were obtained using a construct containing epitopes from melanosomal proteins, indicating that this vaccination was successful in generating responses to self-antigens that potentially may be subjected to immune tolerance. These Wndings are useful for designing DNA vaccines for a multitude of diseases where T lymphocytes play a protective or therapeutic role.
Introduction
There is little doubt that CD8 and CD4 T cells can play a determinant role in the prevention, control, and resolution of many types of infections and malignant disorders. Thus, the design of vaccines capable of inducing eVective antigen-speciWc T cell responses constitutes a top area of research. The deWnition of the minimal antigenic units (epitopes) recognized by T cells as small peptides derived from protein antigens that are presented by MHC molecules has resulted in the development of epitope-based vaccines [1] [2] [3] . Our group has worked for a long time in the use of synthetic peptides representing deWned T cell epitopes in mouse models as vaccine components to induce immune responses capable of displaying antitumor eVects [4] [5] [6] [7] [8] . Being cognizant that vaccines targeting a single MHCrestricted T cell epitope will not oVer broad population coverage due to the limitations imposed by MHC restriction and may become ineVective by the emergence of antigen escape variants, we have devoted some eVorts to the development of multi-epitope vaccines. Initially utilizing a synthetic peptide approach, we described the development of Trojan antigens, which contained several CD8 and one CD4 T cell epitopes joined via furin-sensitive linkers [9] . In addition, the Trojan antigens contained a highly cationic cell-penetrating amino acid sequence (usually from HIVtat), which allowed the construct to enter the MHC-I processing pathway in a TAP-independent manner [10] . Although the peptide-based Trojan antigens induced potent CD8 and CD4 T cell responses, the synthesis and puriWcation of these constructs were challenging and costly due to their large size (»40 amino acids), making it diYcult to take this approach into the clinic. In view of the abovementioned limitations, we now explore the use of cDNAbased vaccination using multi-epitope plasmid constructs in order to induce simultaneous T cell responses in a simpler, practical, and more cost eVective manner. We present here results indicating that intramuscular DNA injections followed by in vivo electroporation (IVE) with multi-epitope plasmids induced strong and eVective antitumor CD8 and CD4 T cell responses. Contrary to our Wndings with peptide Trojan antigens, the multi-epitope DNA vaccines (MEDVs) did not require cationic cell-penetrating sequences or furinsensitive linkers, suggesting a diVerent mode of action. These results generate a new opportunity to the development of multi-epitope T cell vaccines for the treatment/prevention of malignant disorders and infectious diseases.
Materials and methods

Mice and cell lines
Six-to eight-week-old female C57BL/6 and (BALB/c X B6)F1 mice were obtained through the National Cancer Institute/Charles River program (Wilmington, MA). Mice were allowed to acclimate to our animal facility for 1 week before beginning experiments in a pathogen-free environment. All animal care and experiments were conducted according to committee guidelines of our facility. Lo , a variant of B16-F10, was established in our laboratory by transfecting H-2K b into a B16 subline that lost expression of this MHC-I [11] . All cell lines were cultured in DMEM medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin, and 100 g/ml streptomycin (Invitrogen, Grand Island, NY).
Peptides and antibodies
The peptide sequences used in this study are listed in Table 1 . All synthetic peptides were purchased from A&A Labs (San Diego, CA), and the purity (>95%) and identity of the peptides were determined by analytic high-performance liquid chromatography and mass spectrometry analysis. Anti-mouse programmed death ligand-1 mAb (PD-L1; 10F.9G2) was purchased from BioXCell (West lebanon, NH). All Xuorescent antibodies for Xow cytometry were purchased from eBioscience (San Diego, CA).
Construction of multi-epitope DNA vaccines
The template DNA sequences coding several T cell epitopes were designed on the basis of mouse codon usage and were obtained from GenScript (Piscataway, NJ). The plasmids for DNA vaccination were constructed by PCR-based cloning from the DNA templates into the pCI expression vector (Promega, Madison, WI). The constructs contained the combinations of various CD8 T cell epitopes (Ova 257 , SIY, LCMV 33 , PyCSP 280 , LLO 91 , Trp1 455 , Trp2 180 , and hgp100 25 ) linked with either furin-resistant (VRVV) or furin-sensitive (RVKR) spacers. In addition, some of the constructs contained the cell-penetrating sequence, HIV-tat 49 , and a T helper epitope (Ova 323 ). The schematics of the constructs are presented in Fig. 1 and the sequences of the epitopes in Table 1 . Control cDNA vaccines were a pcDNA3 vector coding for chicken ovalbumin (pOva) or an empty pCI vector backbone (pCI). All constructs were conWrmed by DNA sequencing, and DNA was puriWed for vaccination using EndoFree Plasmid Mega Kits (Qiagen, Valencia, CA). 
Immunizations
Anesthetized mice were vaccinated with a total of 100 g of plasmid DNA resuspended in normal saline, injected into both quadriceps femoris muscles. Immunization was followed immediately by electroporation of the injected area (95 V, 4 X 65 ms pulses with repoling) using an Electro Square Porator device (TX830; BTX, San Diego, CA). In some experiments, the mice were given identical booster immunization 2 weeks later. Immune responses were typically measured 8 days after the last immunization.
Evaluation of immune responses
Numbers of antigen-speciWc T cells were measured with EliSpot interferon (IFN )-release assays, performed as described [4] using puriWed CD8 or CD4 T cells from spleens (Miltenyi Biotec; Auburn, CA). BrieXy, responder CD8 T cells were incubated together with peptide-pulsed or unpulsed EL4 cells or with B16 melanoma cells at various responders to stimulator cell ratios in EliSpot plates. Responder CD4 T cells were incubated with peptide-pulsed or unpulsed LB27.4 cells, in a similar manner as described for the CD8 assays. Cultures were incubated at 37°C for 20 h, and spots were developed as described by the EliSpot kit manufacturer (Mabtech, Inc., Mariemont, OH). Spot counting was done with an AID EliSpot Reader System (Autoimmun Diagnostika GmbH, Strassberg, Germany). For intracellular staining, splenocytes from individual mice were incubated with 5 g/ml equivalent peptide for 6 h at 37°C and subsequently stained for intracellular IFN following the directions provided by vendor (BD Bioscience, San Diego, CA) using FITC-conjugated MHC class II, PerCP Cy5.5-conjugated CD8a, and PE-conjugated anti-IFN Abs (eBioscience; San Diego, CA).
Antitumor eVects
In the prophylactic setting, previously immunized mice were challenged with 1 £ 10 5 B16-F10 cells injected through the tail vein 7 days after the booster vaccination. To evaluate the therapeutic eVects of vaccination, mice Wrst received an intravenous inoculation of 1 £ 10 5 B16-F10 cells, and 3 and 18 days later, the mice received their cDNA immunizations. Antitumor eVects were evaluated by the enumeration of lung tumor nodules and measurement of lung weights »4 weeks after tumor injections (when the mice in the non-vaccinated control group became ill). In some experiments, the antitumor eVects were evaluated by survival measurements (time to euthanasia). In addition, a subcutaneous tumor therapeutic model was used, where mice Wrst received a subcutaneous B16 tumor inoculation (3 £ 10 5 or 1 £ 10 5 cells, as indicated), followed 4 days later by the Wrst immunization. Twelve to fourteen days later, the mice were given an identical booster. In some experiments, 200 g of anti-PD-L1 mAb was administered i.p. on days 3, 5, 7, and 9 after each DNA vaccination. Antitumor eVects were evaluated by the measurements of tumor areas. Tumor growth was monitored every 2-4 days in individually tagged mice by measuring two opposing diameters with a set of callipers. Results are presented as the mean tumor size (area in mm 2 ) § SD for every treatment group at various time points until the termination of the experiment.
Statistical analyses
Statistical signiWcance to assess the numbers of antigenspeciWc CD8 T cells (EliSpot) and absolute number of lung tumor nodules were determined by unpaired Student's t tests. Tumor sizes between two populations throughout time were analyzed for signiWcance using 2-way ANOVA. Fig. 1 Multi-epitope plasmid constructs used in this study. pME-1 and pME-2, plasmids coding three well-known CD8 T cell epitopes prepared with two types of linkers, furin-sensitive (RVKR) or furinresistant (VRVV) containing the HIV-tat 49 (RKKRRQRRRR) cationic cell-penetrating sequence. pME-3 and pME-4, similar constructs to pME-1 and pME-2 lacking HIV-tat 49 . pME-5, similar construct to pME-3 but containing a CD4 T cell helper epitope Ova 323 . pME-6, plasmid coding Wve distinct CD8 T cell epitopes and a CD4 T cell helper epitope Ova 323 . pME-7, plasmid coding three CD8 T cell epitopes for melanosomal antigens and a CD4 T cell helper epitope Ova 323 . Sequences for all epitopes and HIV-tat 49 are shown in Table 1 Statistical signiWcance for survival was established by Kaplan-Mayer curves using log-rank tests. All analyses and graphics were done using Prism 5.01 software (GraphPad).
Results
To assess the immunogenicity of MEDVs and determine whether these vaccines functioned in a similar manner as our previously described Trojan antigens [9] , we prepared several cDNA plasmid constructs containing various deWned mouse CD8 T cell epitopes, with and without a CD4 T helper epitope, connected with either furin-sensitive (RVKR) or furin-resistant (VRVV) linkers, and possessing or not a cell-penetrating cationic sequence from HIV-tat ( b -restricted) CD8 T cell epitopes joined to each other with either furin-sensitive or furin-resistant linkers. C57BL/6 mice (B6) received a single i.m. DNA injection immediately followed by electroporation as described in "Materials and methods," and 12 days later, the numbers of functional antigen-speciWc CD8 and CD4 T cells in spleens were enumerated using EliSpot assays. The results in Fig. 2a indicate that all four constructs induced substantial CD8 T cell responses to all three epitopes, regardless of whether or not they contained HIV-tat sequence, furin-sensitive or furin-resistant linkers. Notably, the magnitude of the immune responses was very similar amongst the three epitopes indicating the absence of an overt immune dominance, which could occur due to the position (order) that an epitope occupies within a construct that may aVect its production during antigen processing. Nevertheless, it is possible that the immunogenic potency of the various constructs could diVer amongst themselves when used at lower doses.
Next, we assessed whether the inclusion of an MHC-IIbinding peptide sequence (OVA 323 ) into an MEDV construct (pME-5, Fig. 1 ) would result in the induction of CD4 T cell responses. In addition, we determined whether the magnitude of the CD8 T cell responses would be increased due to the simultaneous stimulation of CD4 T helper cells. The results in Fig. 2b show that the pME-5 MEDV construct containing the OVA 323 CD4 T cell epitope at the carboxyl terminus end was eYcient in generating antigenspeciWc CD4 T cell responses. In addition, a signiWcant increase (40-60%) in the magnitude of the CD8 T cell responses was observed with OVA 323 containing MEDV Fig. 2 Immunogenicity of MEDV constructs encoding foreign CD8 T cell epitopes. Mice (four per group) were vaccinated i.m. with various DNA plasmid constructs (as indicated) followed by electroporation as described in "Materials and methods." On day 12, CD8 and CD4 T cells were puriWed from pooled splenocytes, and antigen-induced IFN secretion to the individual epitopes was evaluated in EliSpot assays using peptide-pulsed APCs. a Role of epitope linkers and cationic cellpenetrating sequence (HIV-tat 49 ) in the immunogenicity of MEDV constructs. b Immunogenicity of a CD4 T helper epitope (Ova 323 ) and potentiating eVect in the CD8 T cell responses of DNA vaccination. Numbers above columns represent the percentage response of the pME-5-immunized mice compared with that of the pME-3-immunized mice. A plasmid containing the ovalbumin cDNA (pOva) was used for comparison. P values were calculated using the two-way ANOVA test between the pME-5-immunized and the pME-3-immunized group. c CD8 T cell responses to vaccination using a MEDV construct containing Wve distinct CD8 T cell epitopes in CB6F1 mice. EL4 (H-2 b ) and P815 (H-2 d ) cells pulsed with the corresponding peptides were used as APCs to evaluate the CD8 T cell responses, and LB27.4 (I-A b ) cells were used to evaluate the CD4 T cell response to Ova 323 . Results represent the average number of spots from triplicate wells with SD (error bars) of the means. Representative results of data were obtained from two diVerent experiments ᭣ construct, as compared to the pME-3 construct, which only contained the three CD8 epitopes. For comparison, we tested the immunogenicity of a cDNA construct encoding the entire ovalbumin protein (pOva). Notably, the immune responses to both the CD8 and the CD4 Ova T cell epitopes generated by the pME-5 MEDV expressing the T helper Ova 323 sequence were approximately 25% higher than those generated with the pOva construct.
The results presented so far indicate that plasmids containing up to three CD8 T cell epitopes (and a CD4 epitope) are eYcient in generating immune responses of similar magnitude to all the components. Next, we determined whether the inclusion of two additional CD8 T cell epitopes, in this case restricted by a diVerent MHC-I allele (H-2 d ) would continue to elicit responses of equal intensity to all the epitopes. As shown in Fig. 2c , (BALB/c X B6), F1 mice immunized with the pME-6 MEDV, containing Wve CD8 T cell epitopes, three restricted by H-2 b and two by H-2 d (Fig. 1 ), elicited T cell responses of approximately similar magnitude to all the Wve epitopes. In addition, CD4 T cell responses to the Ova 323 epitope were maintained at similar levels as those previously observed with the pME-5 construct (data not shown).
To evaluate whether the CD8 T cell responses invoked by MEDVs exhibit any activity in a disease setting, we prepared a cDNA construct containing three CD8 T cell epitopes derived from melanosomal proteins (Trp1, Trp2, and gp100) expressed by the transplantable B16 melanoma cell line (pME-7, Fig. 1 ). Since these antigens are also expressed by normal melanocytes, an eVective vaccination must be able to overcome potential immune tolerance. Immunization of B6 mice following the same protocol as with the previous experiments (single i.m. immunization followed by electroporation) resulted in CD8 T cell responses that were somewhat lower (»2-fold) as those generated using MEDVs composed of foreign antigens (data not shown). In view of this, we administered two sequential immunizations (prime-boost, 2 weeks apart). Substantial immune responses were clearly evident to all three melanoma epitopes as measured by intracellular cytokine staining (Fig. 3a) . Again, the magnitude of the responses amongst the three epitopes was of a similar range. These results indicate that the melanosomal MEDV was eVective in overcoming any potential immune tolerance to antigens that are expressed by normal tissues. However, it would be expected that CD8 T cells reactive with the melanosomal antigens would be recruited from low to intermediate avidity precursors that have escaped central and peripheral tolerance and will only respond to high levels of antigen and may not be eVective in recognizing the melanoma tumor cells. Nonetheless, as demonstrated in Fig. 3b, CD8 T cells from spleens of vaccinated mice were eVective in recognizing not only the peptide-pulsed APCs (EL4 cells), but also B16 melanoma cells.
Having shown that the melanosomal MEDV construct was immunogenic, capable of inducing similar levels of immune responses as those observed with constructs containing T cell epitopes from foreign antigens, we proceeded to study the in vivo antitumor eVects of this vaccination strategy. In the prophylactic setting (tumor challenge after vaccination), the MEDV was completely eVective in preventing the establishment of lung tumor colonies, when B16 cells were injected intravenously 7 days after the second immunization (Fig. 4a) . In a more realistic tumor model, therapeutic vaccination 3 days post-tumor inoculation, the MEDV showed a signiWcant beneWt as compared to the control vaccine, reducing the number of tumors by approximately 50% (Fig. 4b) . In a survival experiment, therapeutic vaccination increased medium survival time by approximately 12 days in this very aggressive tumor model where all control mice perished by day 28 post-tumor inoculation (Fig. 4c) .
We have recently reported that IFN has a negative eVect in the eYcacy of peptide vaccination in the B16 melanoma model [11] . We observed that CD8 T cells from peptide-vaccinated mice poorly recognized B16 cells Fig. 3 Evaluation of a MEDV construct containing melanoma-relevant CD8 T cell epitopes. B6 mice (four per group) were vaccinated i.m. on days 0 and 14 with plasmid pME-7, which is coding three melanosomal antigen-derived CD8 T cell epitopes (Table 1 and (1) enhanced expression of non-cognate (irrelevant) MHC-I molecules, which could sequester CD8 co-receptors outside of the immune synapse, limiting T cell activation; and (2) induction of the expression of PD-L1 (also known as B7-H1) inhibitory molecules. Thus, when a B16 tumor subline (B16-Kb Lo ) that does not overexpress MHC-I when treated with IFN was used in combination with PD1 blockade, peptide vaccination was able to completely eradicate large established subcutaneous tumors [11] . These observations suggest that limiting the negative eVects of IFN may increase the eYcacy of MEDVs against B16 melanoma. We Wrst determined whether IFN -treatment of B16 cells would decrease the recognition by CD8 T cells from the melanosomal MEDV-immunized mice. As shown in Fig. 5a , the IFN -treated B16 cells were recognized less eVectively (»66%) as compared to the untreated cells. In view of this, we evaluated the eVectiveness of the melanosomal MEDV against the B16-Kb Lo cell line in a therapeutic subcutaneous model both in the presence and in the absence of PD-1 blockade. The results presented in Fig. 5b illustrate that the MEDV administered by itself had a minimal, but signiWcant therapeutic eVect in limiting B16-Kb Lo tumor Fig. 4 DNA vaccination coding multiple melanoma-speciWc CD8 T cell epitopes results in strong antitumor eVects. a Prophylactic antitumor eVect of MEDV immunization. B6 mice (four per group) were immunized on days -25 and -7 with either pME-7 or control backbone plasmid pCI, followed by electroporation. Seven days after last immunization, the mice received 1 £ 10 5 B16 melanoma cells administered i.v. and on day 28 (when the control mice started to appear ill), and the presence of B16 pulmonary nodules was evaluated. b Therapeutic antitumor eVect of DNA vaccination. B6 mice (four per group) received 1 £ 10 5 B16 cells i.v. and 3 and 18 days later, and the mice were vaccinated with either pME-7 or pCI, followed by electroporation. On day 26 (when the control mice started to appear ill), the presence of B16 pulmonary tumors was evaluated. Results for a and b are presented as "number of lung tumors" and "lung weights" for individual mice. When lung foci were too numerous to count, they are shown as >300. Each data point represents the number of lung foci and its lung weight in mgs for each individual mouse, and horizontal line represents the average value of the group. Representative photographs of lungs of two mice from each group are shown. P values were calculated using unpaired Student's t test. c Therapeutic MEDV immunization results in increased survival advantage. Using the same experimental protocol presented in panel b, mice (eight per group) were studied for their survival (time to euthanasia). Graph represents the percentage of mice in each group that survived overtime after the tumor injection. P value was determined by log-rank test progression. On the other hand, MEDV administered in combination with anti-PD-L1 antibodies had a dramatic therapeutic eVect. In a similar therapeutic vaccination experiment, but using conventional B16 cells (which express high levels of MHC-I after IFN treatment), the results showed that MEDV alone had no signiWcant eVect on tumor progression, but that vaccination with PD-1 blockade demonstrated a small, but signiWcant eVect (Fig. 5c) . These results indicate that as with peptide vaccination, IFN exerts a negative eVect in the therapeutic eYcacy of MEDVs against established tumors in the B16 melanoma system. However, signiWcant therapeutic eVects can be obtained in circumstances when these negative eVects are overcome. , and were vaccinated with plasmid pME-7 followed by electroporation on days 4 and 18. Anti-PD-L1 mAb was administered i.p. on days 3, 5, 7, and 9 after each DNA vaccination. Control plasmid pCI-vaccinated mice inoculated with the same number of tumor cells were included as controls. Tumor sizes were determined in individual mice by the measurements of two opposing diameters and are presented as tumor areas in mm 2 . Points mean for each group of mice; gray bars, period of anti-PD-L1 mAb treatment; and bars, SD. P value was calculated using two-way ANOVA test. These experiments were repeated twice with similar results. c Similar experiment as presented in panel b, but using unmodiWed B16 cells that express normal levels of H-2K b , which can be increased by IFN
Discussion
In this report, we have presented evidence that DNA vaccination with constructs containing multiple epitopes results in the induction of strong CD8 and CD4 T cell responses to all the components of the vaccines. It remains to be determined whether this approach will function with constructs containing more than Wve CD8 T cell epitopes and whether an upper limit in the number of epitopes exists before antigenic competition becomes evident. Nevertheless, this approach allows the simultaneous induction of T cell responses to numerous epitopes using a single entity, which is essential to oVer broad population coverage, due to extensive polymorphic nature of the MHC. In addition, by targeting more than one T cell epitope, the probability of the emergence of escape variants should hopefully be reduced.
Our original intent was to design MEDVs to produce immunogens that would function in a similar manner as the peptide-based multi-epitope Trojan antigens that we previously studied, which generate strong T cell responses [9] . The Trojan antigens relied on a cell-penetrating cationic sequence to enter the antigen-processing pathway in a TAP-independent manner and required furin-sensitive linkers to produce individual MHC-I-binding peptides [9, 10] . We were somewhat surprised by the results that the presence of the cationic HIV-tat sequence and furin-sensitive linkers was not required for the MEDVs to exhibit immunogenicity (Fig. 2a) . Moreover, the presence of HIV-tat and furin-sensitive linkers did not signiWcantly increase the level of CD8 T cell responses. These results suggest that the mode of action of immunogenicity of the MEDVs diVers substantially from that of the peptidic Trojan antigens. Intramuscular injection of plasmid DNA followed by electroporation results in high levels of the expression of the gene product [12, 13] . However, our constructs do not include a leader sequence, so it would not be expected that the transduced muscle cells would secrete the translation products. Most likely, as with other DNA-based vaccines that are administered intramuscularly, many of the muscle cells may be damaged by the subsequent electroporation intended to increase DNA uptake, and later die providing cell debris rich in antigen and danger/adjuvant signals [14] [15] [16] , leading to the activation of professional APCs and initiating the T cell immune response. There are other reports of DNA-based vaccination approaches using constructs containing multiple T cell epitopes [17] [18] [19] [20] [21] . In a report by Livingston et al. [20] , DNA constructs containing up to 20 CD8 T cell epitopes described that the magnitude of the T cell responses varied enormously (in some cases more than 90%) from epitope to epitope and ascribed this to diVerences in antigen processing of the cDNA products.
This group also reported that a basic (K and R), amide (Q and N), or small (C, G, A, T, and S) residue in linkers Xanking the C-terminal end of the epitope improved the immunogenicity. Our studies showed that the furin-sensitive and furin-resistant linkers, which place an R or a V (considered bulky) residue, respectively, in this position worked equally well in generating strong immune responses. At this time we do not know whether the two linkers we used are important or not for the generation of the individual epitopes through antigen processing, and whether other specialized linker types such as AAY [21] or simply the blunt joining of the epitopes to each other will suYce. The disparity between our results and those of Livingston could be due to one or more diVerences of the systems in addition to the type of linkers used, such as numbers of epitopes per construct, presence of leader sequence (in their constructs), and lack of electroporation (in their vaccine).
These results demonstrate that little, if any antigenic competition was observed with the MEDV constructs allowing the induction of T cell responses to up to Wve distinct CD8 T cell epitopes, without any evidence of immunodominance, since all the responses were basically of equivalent intensity. It has been reported that naïve T cell precursor frequencies and peptide MHC-I-binding aYnities dictate to a large extent the immunodominance hierarchy of T cell responses to antigens or pathogens containing multiple epitopes [22] . Other factors involved in antigen processing (proteasomal cleavage and transport to the ER), which determine the amount of peptide epitopes produced may also aVect the degree of immunodominance [23] . It is likely that all Wve foreign epitopes in pME-6 and the three melanosomal epitopes in pME-7 bind to their respective MHC-I molecules with various degrees of aYnity and that the naïve T cell precursor frequencies will vary substantially between these epitopes. Thus, we Wnd it quite remarkable that the MEDVs generated T cell responses of similar magnitude to all epitopes within each construct. We believe that the plasmid constructs used in our experiments are eVective in producing all the peptide epitopes within their sequence in suYcient amounts, allowing sustained antigen presentation resulting in successful T cell activation and clonal expansion, regardless of some diVerences in precursor frequency and MHC-I-binding aYnities. Nevertheless, it is certain that a speciWc threshold in the MHC-binding strength of a peptide must be met in order for the epitope within a construct to generate a T cell response. Regardless of the exact mode of action, the MEDVs described here proved to be eVective in generating T cell responses in mice. It remains to be determined whether this approach will function in primates, where DNA vaccination in general has been more challenging.
